ATE309775T1 - Die verwendung von prostaglandin f analoga zur herstellung von zusammensetzungen für die behandlung von haarausfall. - Google Patents

Die verwendung von prostaglandin f analoga zur herstellung von zusammensetzungen für die behandlung von haarausfall.

Info

Publication number
ATE309775T1
ATE309775T1 AT01926506T AT01926506T ATE309775T1 AT E309775 T1 ATE309775 T1 AT E309775T1 AT 01926506 T AT01926506 T AT 01926506T AT 01926506 T AT01926506 T AT 01926506T AT E309775 T1 ATE309775 T1 AT E309775T1
Authority
AT
Austria
Prior art keywords
compositions
hair loss
prostaglandin
analogues
preparation
Prior art date
Application number
AT01926506T
Other languages
English (en)
Inventor
Mitchell Anthony Delong
John Mcmillan Mciver
Robert Scott Youngquist
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22714441&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE309775(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Application granted granted Critical
Publication of ATE309775T1 publication Critical patent/ATE309775T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4986—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with sulfur as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01926506T 2000-03-31 2001-03-30 Die verwendung von prostaglandin f analoga zur herstellung von zusammensetzungen für die behandlung von haarausfall. ATE309775T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19364500P 2000-03-31 2000-03-31
PCT/US2001/010370 WO2001074315A2 (en) 2000-03-31 2001-03-30 Compositions and methods for treating hair loss using non-naturally occurring prostaglandins

Publications (1)

Publication Number Publication Date
ATE309775T1 true ATE309775T1 (de) 2005-12-15

Family

ID=22714441

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01926506T ATE309775T1 (de) 2000-03-31 2001-03-30 Die verwendung von prostaglandin f analoga zur herstellung von zusammensetzungen für die behandlung von haarausfall.

Country Status (10)

Country Link
US (10) US20020172693A1 (de)
EP (1) EP1267807B1 (de)
JP (7) JP2003528899A (de)
CN (3) CN100384425C (de)
AT (1) ATE309775T1 (de)
AU (1) AU2001253039A1 (de)
CA (1) CA2401731C (de)
DE (1) DE60115000T2 (de)
ES (1) ES2252215T3 (de)
WO (1) WO2001074315A2 (de)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000051980A1 (en) 1999-03-05 2000-09-08 The Procter & Gamble Company C16 unsaturated fp-selective prostaglandins analogs
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020146439A1 (en) * 2000-03-31 2002-10-10 Delong Mitchell Anthony Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins
US20020037914A1 (en) * 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
CA2449462A1 (en) * 2001-07-25 2003-02-06 Alcon, Inc. Methods for promotion of hair growth comprising topical application of prostaglandin analogues
US8758733B2 (en) 2002-02-04 2014-06-24 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
US9216183B2 (en) 2002-02-04 2015-12-22 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
US7351404B2 (en) * 2002-02-04 2008-04-01 Allergan, Inc. Method of enhancing hair growth
US20030199590A1 (en) * 2002-07-25 2003-10-23 Cagle Gerald D Prostaglandin analogues for promotion of hair growth
US7326717B2 (en) 2003-05-06 2008-02-05 L'oreal Pyrimidine n-oxide compounds for stimulating the growth of keratin fibers and/or reducing loss thereof
TWI348386B (en) * 2003-08-12 2011-09-11 R Tech Ueno Ltd Composition and method for promoting hair growth
WO2006047466A2 (en) * 2004-10-21 2006-05-04 Duke University Ophthamological drugs
WO2007023841A1 (ja) * 2005-08-25 2007-03-01 Taisho Pharmaceutical Co., Ltd. 発毛剤組成物
WO2007111806A2 (en) 2006-03-23 2007-10-04 Massachusetts Eye And Ear Infirmary Cyclopentane heptanoic acid compounds for reducing body fat
US20070254920A1 (en) * 2006-04-26 2007-11-01 Aerie Pharmaceuticals, Inc. Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use
US7879910B1 (en) * 2006-10-10 2011-02-01 Jan Marini Skin Research, Inc. Compositions and methods for promoting lush hair growth
US20080096782A1 (en) * 2006-10-19 2008-04-24 L'oreal Aqueous systems containing phospholipid, surfactant and phosphate ester for water-insoluble materials
US20080097070A1 (en) * 2006-10-19 2008-04-24 L'oreal Aqueous polyamine-containing systems for water-insoluble materials
ITMI20071073A1 (it) * 2007-05-25 2008-11-26 Ctg Pharma S R L Composizioni farmaceutiche di prostaglandine
FR2920309B1 (fr) 2007-08-28 2010-05-28 Galderma Res & Dev Utilisation de travoprost pour traiter la chute des cheveux
WO2009045908A2 (en) * 2007-09-28 2009-04-09 Cayman Chemical Company A method for screening of prostaglandin compounds comprising an optimal formulation for the enhancement of hair growth and the stimulation of follicular anagen and formulations resulting therefrom
WO2010039535A1 (en) * 2008-09-23 2010-04-08 Meta Cosmetics, Llc Compositions and methods to treat epithelial-related conditions
WO2009058493A1 (en) * 2007-10-31 2009-05-07 Pamela Lipkin Prostaglandin analog compositions and methods to treat epithelial-related conditions
US7744995B2 (en) * 2007-12-18 2010-06-29 Toyota Motor Engineering & Manufacturing North America, Inc. Multi-layer coatings for substrates
WO2009140430A1 (en) * 2008-05-14 2009-11-19 Peter Thomas Roth Labs, Llc Prostaglandin based compositions and method of use thereof
EP2153836A1 (de) * 2008-08-04 2010-02-17 Polichem S.A. Filmbildende flüssige Formulierungen zur Wirkstofffreisetzung im Haar und auf der Kopfhaut
BRPI0918244A2 (pt) 2008-09-04 2015-12-15 Santen Pharmaceutical Co Ltd E Asahi Glass Company Ltd agente promotor do crescimento de pelos, e método para prevenir ou tratar uma doença associada com os cabelos.
US8722739B2 (en) 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8623918B2 (en) 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US20100204335A1 (en) * 2008-12-01 2010-08-12 Allergan, Inc. Kit and composition for eyelash growth
WO2010064203A1 (en) 2008-12-02 2010-06-10 L'oreal Combination of reduced glutathione and amino acids for improving the quality of the hair in women
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
EP3871671A3 (de) 2009-07-29 2022-03-09 Olsen, Elise Fp rezeptorantagonisten zur hemmung von haarwachstum
FR2949052B1 (fr) 2009-08-13 2015-03-27 Oreal Procede de traitement cosmetique du cuir chevelu.
WO2011034940A1 (en) 2009-09-15 2011-03-24 Five Prime Therapeutics, Inc. Hair growth methods using fgfr4 extracellular domains
US9149484B2 (en) * 2009-11-09 2015-10-06 Allergan, Inc. Compositions and methods for stimulating hair growth
NZ628266A (en) * 2009-11-09 2016-02-26 Allergan Inc Compositions and methods for stimulating hair growth
WO2011084711A2 (en) 2009-12-17 2011-07-14 Five Prime Therapeutics, Inc. Hair growth methods using fgfr3 extracellular domains
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
WO2013172838A1 (en) * 2012-05-17 2013-11-21 Steven Yoelin Compositions and methods for hair growth
WO2012092628A2 (en) * 2010-12-31 2012-07-05 Incube Labs, Llc Patches and methods for the transdermal delivery of agents to treat hair loss
EP3378480A1 (de) 2011-01-19 2018-09-26 Topokine Therapeutics, Inc. Verfahren und zusammensetzungen zur behandlung des stoffwechselsyndroms
US8859616B2 (en) 2011-01-21 2014-10-14 Allergan, Inc. Compounds and methods for enhancing hair growth
US8426471B1 (en) 2011-12-19 2013-04-23 Topokine Therapeutics, Inc. Methods and compositions for reducing body fat and adipocytes
WO2013158649A1 (en) 2012-04-16 2013-10-24 Case Western Reserve University Compositions and methods of modulating 15-pgdh activity
CA2874288A1 (en) * 2012-05-30 2013-12-05 Asahi Glass Company, Limited Composition for hair growth
NO2753788T3 (de) 2013-05-10 2018-06-16
WO2014182908A1 (en) * 2013-05-10 2014-11-13 Topical Solutions, Inc. Compositions and methods for treating nails, claws, and hoofs
US9820993B2 (en) * 2013-05-15 2017-11-21 Topokine Therapeutics, Inc. Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
US9789116B2 (en) 2013-10-15 2017-10-17 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
US9913849B2 (en) * 2014-01-10 2018-03-13 Manistee Partners Llc Treatment of migraines
US10188661B2 (en) 2014-06-27 2019-01-29 Topokine Therapeutics, Inc. Topical dosage regimen
JP6686023B2 (ja) * 2014-11-25 2020-04-22 エキシモア・リミテッドＥｘｉｍｏｒｅ Ｌｔｄ． 生物活性剤または生物活性剤類を送達する組成物および方法
WO2017068604A1 (en) * 2015-10-22 2017-04-27 Deltahex Innovation Pvt. Ltd Hair growth stimulant and preparation method thereof
US11185487B2 (en) * 2015-12-28 2021-11-30 Johnson & Johnson Consumer Inc. Hair growth composition and method
US10136438B2 (en) * 2016-01-22 2018-11-20 Space Systems/Loral, Inc. Flexible bandwidth assignment to spot beams
DE102016110381A1 (de) * 2016-06-06 2017-12-07 Edwin Kohl Kosmetische Zusammensetzung, insbesondere zur Förderung des Haarwuchses
KR102275012B1 (ko) 2016-08-12 2021-07-07 실크 테크놀로지스 리미티드 염증 치료용 실크 유래 단백질
WO2018102552A1 (en) 2016-11-30 2018-06-07 Case Western Reserve University Combinations of 15-pgdh inhibitors with corcosteroids and/or tnf inhibitors and uses thereof
US11718589B2 (en) 2017-02-06 2023-08-08 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase
KR101831947B1 (ko) * 2017-09-20 2018-02-23 아주대학교산학협력단 아토르바스타틴을 유효성분으로 포함하는 난청의 예방 또는 치료용 조성물
US11185530B2 (en) 2017-03-09 2021-11-30 Ajou University Industry-Academic Cooperation Foundation Composition for preventing or treating hearing loss, containing atorvastatin as active ingredient
WO2019113210A1 (en) 2017-12-05 2019-06-13 Anthos Partners, Lp Phosphonium-based ionic drug conjugates
KR102921276B1 (ko) 2018-11-21 2026-02-03 케이스 웨스턴 리저브 유니버시티 단쇄 데히드로게나아제 활성을 조절하는 조성물 및 방법
US12539302B2 (en) 2019-08-07 2026-02-03 Aneira Pharma, Inc. Methods and compositions for the treatment of hair loss
US12226415B2 (en) 2019-08-07 2025-02-18 Aneira Pharma, Inc. Methods and compositions for the treatment of hair loss
EP4057941A4 (de) 2019-11-15 2024-05-29 Silk Technologies Ltd. Stabile formulierungen von seide-abgeleitetem protein
MX2022014637A (es) 2020-05-20 2023-03-03 Rodeo Therapeutics Corp Composiciones y metodos para modular la actividad de deshidrogenasas de cadena corta.
US11850300B2 (en) 2022-03-17 2023-12-26 Rally Guide Topical lotion composition, methods of use, and methods of preparation

Family Cites Families (325)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US37914A (en) * 1863-03-17 Improved automatic nose-bag
US13294A (en) * 1855-07-17 Improved apparatus for cooling repeating fire-arms
US37913A (en) * 1863-03-17 Improvement in sewing-machines
US146439A (en) * 1874-01-13 Improvement in pruning-shears
DE1617477U (de) 1950-09-27 1950-12-14 Heinrich Dressel Radhalter fuer raeder, beispielsweise fuer kinderwagen und kleinfahrzeuge.
US3776938A (en) 1958-05-28 1973-12-04 S Bergstrom Dihydro-pge1
US3069322A (en) 1958-05-28 1962-12-18 Bergstrom Sune Pge and pgf
US3776939A (en) 1958-05-28 1973-12-04 S Bergstrom Dihydro-pgf1a
US3839409A (en) * 1958-05-28 1974-10-01 Kemiska Inst Karolinska I Pge3 esters and alkanoates
DE1801750U (de) 1959-07-07 1959-12-10 H L Wahrendorf Betonwerk Trog zur aufnahme des weichengestaenges von eisenbahngleisen.
US3382247A (en) * 1965-11-01 1968-05-07 Upjohn Co 6-amino-1, 2-dihydro-1-hydroxy-2-imino-4-phenoxypyrimidines
US3435053A (en) * 1966-06-06 1969-03-25 Upjohn Co Cyclopenta(b)pyrans
US3524867A (en) * 1966-06-06 1970-08-18 Upjohn Co Process for producing cyclopenta (b)pyrans
US3538120A (en) 1967-05-22 1970-11-03 Ciba Geigy Corp Cyclopentyl-alkanoic acids
US3636120A (en) 1967-10-09 1972-01-18 Upjohn Co Prostaglandin e primary alcohols
GB1285371A (en) 1968-08-29 1972-08-16 Upjohn Co Improvements in or relating to therapeutic methods using prostaglandins
GB1251750A (de) 1968-11-12 1971-10-27
DE1910561A1 (de) 1969-03-01 1970-09-10 Herten Dr Med Kurt Mittel zur Verhuetung von Haarausfall
BE755555A (fr) * 1969-09-02 1971-03-01 Richardson Merrell Inc Derives de quinoxaline
US3882241A (en) * 1969-12-01 1975-05-06 Upjohn Co Use of prostaglandins E and F for prevention of pregnancy in humans
US3896156A (en) * 1970-06-30 1975-07-22 Upjohn Co Dihydroprostaglandin e, analogs
IT1012505B (it) 1970-09-28 1977-03-10 Imes C Spa Estratto di ricci di mare
GB1324737A (en) 1970-11-02 1973-07-25 Upjohn Co Prostaglandins and the preparation thereof
US4124720A (en) 1970-11-09 1978-11-07 Wenmaekers Georges E J Therapeutic hydrodispersible emulsion
JPS5212919Y2 (de) 1971-06-14 1977-03-23
BE791369A (fr) 1971-11-16 1973-05-14 American Cyanamid Co Cyanurates de tris-(meta-hydroxybenzyle) faisant l'objet d'un empechement sterique et utilisables comme anti-oxydants
JPS525744Y2 (de) 1972-03-18 1977-02-05
US3798275A (en) 1972-04-05 1974-03-19 Ciba Geigy Corp Etherified mercapto-methoxyamines
US4304907A (en) 1972-05-10 1981-12-08 The Upjohn Company Bicyclo lactone intermediates for prostaglandin analogs
US4011262A (en) * 1972-07-13 1977-03-08 Pfizer Inc. 13,14-Dihydro-15-substituted-ω-pentanorprostaglandins of the two series
US3974213A (en) * 1972-07-13 1976-08-10 Pfizer Inc. 13,14-Dihydro-15-substituted-ω-pentanorprostaglandins
JPS4969636U (de) 1972-09-29 1974-06-18
JPS5220141Y2 (de) 1972-10-13 1977-05-10
US3882245A (en) * 1972-11-01 1975-05-06 Upjohn Co Use of prostaglandins in combating shock
DD118856A5 (de) 1972-11-08 1976-03-20
US4024179A (en) * 1972-11-08 1977-05-17 Pfizer Inc. Substituted ω-pentanorprostaglandins
IL50310A (en) 1972-11-08 1977-08-31 Pfizer Dimethyl ketophosphonates
US3984424A (en) * 1972-11-08 1976-10-05 Pfizer Inc. P-biphenyl esters of 15-substituted-ω-pentanorprostaglandins
US4152527A (en) * 1972-11-08 1979-05-01 Pfizer Inc. 15-Substituted-ω-pentanorprostaglandins
JPS4993342U (de) 1972-12-05 1974-08-13
JPS5253841Y2 (de) 1972-12-12 1977-12-07
JPS49100071U (de) 1972-12-20 1974-08-28
JPS49101356U (de) 1972-12-20 1974-08-31
JPS5320995Y2 (de) 1972-12-23 1978-06-02
JPS5720305B2 (de) 1973-02-28 1982-04-27
US3984455A (en) * 1973-07-16 1976-10-05 The Upjohn Company Prostaglandin E1 analogs
JPS5118118Y2 (de) 1973-07-17 1976-05-14
FR2239458A1 (en) 1973-07-31 1975-02-28 Aries Robert Prostaglandin amides - with antilipolytic, gonadotrophic, luteolytic, hypotensive and other activities associated with prostaglandins
DE2365101A1 (de) * 1973-12-21 1975-07-10 Schering Ag Neue prostansaeurederivate und verfahren zu ihrer herstellung
US3931282A (en) 1974-02-21 1976-01-06 Syntex (U.S.A.) Inc. 11α-Hydroxymethyl prostaglandins
US3928588A (en) 1974-02-22 1975-12-23 Upjohn Co Method of reducing the undesirable gastrointestinal effects of prostaglandin synthetase inhibitors
DE2416193C2 (de) 1974-04-03 1985-08-14 Hoechst Ag, 6230 Frankfurt Prostaglandin-Analoge, Verfahren zu ihrer Herstellung sowie ihre Verwendung als cytoprotektives Mittel
GB1458315A (en) * 1974-04-22 1976-12-15 Ici Ltd Prostanoic acid derivatives
JPS50142539U (de) 1974-05-13 1975-11-25
JPS50157344U (de) 1974-06-12 1975-12-26
DE2460990A1 (de) 1974-12-21 1976-07-01 Hoechst Ag Neue prostaglandin-analoga und verfahren zu ihrer herstellung
JPS5186449U (de) 1974-12-30 1976-07-10
GB1507211A (en) 1975-02-14 1978-04-12 Ono Pharmaceutical Co Prostaglandin analogues
US3934013A (en) * 1975-02-21 1976-01-20 Syntex (U.S.A.) Inc. Pharmaceutical composition
US4217360A (en) * 1975-02-27 1980-08-12 Schering Aktiengesellschaft Novel 1,3-benzodioxaneprostanoic acid derivatives and process for the preparation thereof
GB1506817A (en) * 1975-03-31 1978-04-12 Upjohn Co Prostaglandins
DE2517771A1 (de) * 1975-04-18 1976-10-28 Schering Ag Neue prostaglandin-acetylen-analoga und verfahren zu ihrer herstellung
JPS5328160Y2 (de) 1975-05-16 1978-07-15
GB1520522A (en) 1975-06-16 1978-08-09 Ono Pharmaceutical Co 16-methyleneprostaglandins
ES449162A1 (es) 1975-06-23 1977-12-16 Syntex Inc Un procedimiento para la preparacion de un compuesto racemi-co u 8r-antimerico.
US4005133A (en) 1975-10-14 1977-01-25 The Upjohn Company PGF2.sub.α, L-Arginine salt
US4128577A (en) 1975-12-29 1978-12-05 The Upjohn Company 15-Methyl- and 16-phenoxy-PGF2 α, amides
US4158667A (en) * 1976-02-04 1979-06-19 The Upjohn Company 6-Keto PGF analogs
US4139619A (en) * 1976-05-24 1979-02-13 The Upjohn Company 6-Amino-4-(substituted amino)-1,2-dihydro-1-hydroxy-2-iminopyrimidine, topical compositions and process for hair growth
US4596812A (en) * 1976-05-24 1986-06-24 The Upjohn Company Methods and solutions for treating male pattern alopecia
US4051238A (en) * 1976-06-03 1977-09-27 The Upjohn Company Treatment of genital tract diseases of domestic animals with prostaglandins
US4268522A (en) * 1976-06-14 1981-05-19 Pfizer Inc. 13,14-Dihydro-15-alkenyl- and 13,14-dihydro-15-alkynyl prostaglandins and analogs thereof
DE2635985A1 (de) * 1976-08-06 1978-02-09 Schering Ag Prostansaeurederivat und verfahren zu ihrer herstellung
DE2737808A1 (de) 1976-08-27 1978-03-16 Pfizer 2-substituierte aryl-heterocyclische omega-pentanorprostaglandine
DE2737807A1 (de) 1976-08-27 1978-03-09 Pfizer C tief 1 -p-biphenylester von omega-pentanorprostaglandinen
US4123441A (en) * 1976-09-22 1978-10-31 The Upjohn Company Enlarged-hetero-ring prostacyclin analogs
US4499293A (en) * 1976-09-22 1985-02-12 The Upjohn Company PGI2 Salts
US4089885A (en) * 1976-11-05 1978-05-16 American Home Products Corporation Prostaglandin derivatives
US4171331A (en) * 1978-06-05 1979-10-16 Miles Laboratories, Inc. 1 And 2-substituted analogues of certain prostaglandins
US4178457A (en) 1978-07-10 1979-12-11 Syntex (U.S.A.) Inc. (dl)-16-Phenoxy- and 16-substituted phenoxy-9-keto prostatrienoic acid derivatives and processes for the production thereof
US4206151A (en) * 1978-12-21 1980-06-03 American Cyanamid Company 15-Deoxy-16-hydroxy-16-vinyl or cyclopropyl prostan-1-ols of the E, A and F series
US4311707A (en) * 1979-02-12 1982-01-19 American Cyanamid Company Process for topically producing cutaneous vasodilation for the treatment of vasospastic or ischemic conditions
GB2048254B (en) 1979-04-02 1983-05-25 Upjohn Co 19,20 -didehydro-19-hydroxy and 19-oxo-prostaglandin derivatives
JPS5829710Y2 (ja) 1979-05-25 1983-06-29 スガツネ工業株式会社 錠前
US4225507A (en) * 1979-07-05 1980-09-30 The Upjohn Company 19-Hydroxy-19-methyl-PGI2 compounds
US4225508A (en) * 1979-07-05 1980-09-30 The Upjohn Company 19-Hydroxy-PGI2 compounds
US4296504A (en) * 1980-07-07 1981-10-27 Lawson Daniel C Toilet seat lock
JPS6032763Y2 (ja) 1980-09-06 1985-09-30 日興エンジニアリング株式会社 液体充填装置
JPH0222226Y2 (de) 1981-02-04 1990-06-14
US4621100A (en) 1981-09-25 1986-11-04 The Upjohn Company Treatment of osteoporosis with prostaglandins
US4543353A (en) 1981-11-27 1985-09-24 Farmitalia Carlo Erba S.P.A. Ester and amide derivatives of 13,14-didehydro prostaglandins
US4599353A (en) * 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
US4912235A (en) 1983-12-22 1990-03-27 Syntex (U.S.A.) Inc. Processes and intermediates for making 16-phenoxy- and 16-substituted phenoxy-prostatrienoic acid derivatives and their stereoisomers
WO1986000616A1 (en) 1984-07-13 1986-01-30 Gail Sansone Bazzano Substituted pyrimidine oxides useful for hair growth promotion
AU573018B2 (en) 1984-07-31 1988-05-26 Syntex (U.S.A.) Inc. 11-substituted 16-phenoxy prostatrienoic acid derivatives
JPS6134778U (ja) 1984-07-31 1986-03-03 株式会社明電舎 電気機器収納箱
JPS61126069A (ja) * 1984-11-21 1986-06-13 Res Dev Corp Of Japan プロスタグランジン誘導体
JPS61218510A (ja) * 1985-03-22 1986-09-29 Dai Ichi Seiyaku Co Ltd 毛髪用剤
US5863948A (en) * 1985-06-14 1999-01-26 Massachusetts Eye And Ear Infirmary Increasing aqueous humor outflow
US4757089A (en) * 1985-06-14 1988-07-12 Massachusetts Eye And Ear Infirmary Increasing aqueous humor outflow
US4704386A (en) 1985-08-29 1987-11-03 G. D. Searle & Co. 8-chlorodibenz[b,f][1,4]oxazepine-10(11H)-carboxylic acid, 2-[(phenylsulfinyl-, and phenylsulfonyl)alkanoyl]hydrazides
US4883819A (en) 1986-07-31 1989-11-28 The Trustees Of Columbia University In The City Of New York Use of A, B and C prostaglandins and derivatives thereof to treat ocular hypertension and glaucoma
US4889845A (en) 1986-06-09 1989-12-26 American Cyanamid Company Vehicle for topical application of pharmaceuticals
FI872552A7 (fi) * 1986-06-09 1987-12-10 American Cyanamid Co Paikallisesti käytettävä prostaglandiinikoostumus.
US5041439A (en) * 1986-06-13 1991-08-20 The Procter & Gamble Company Penetrating topical pharmaceutical compositions
US5663203A (en) * 1986-09-11 1997-09-02 Schering Aktiengesellschaft Agents containing prostacyclin derivatives for topical application
US5500230A (en) * 1987-01-23 1996-03-19 The General Hospital Corporation Method for treatment of glaucoma with nitrogen containing guanylate cyclase activators
US5219885A (en) 1987-02-16 1993-06-15 Froelich Juergen Prostaglandin E1 derivatives as pharmaceutically active agents, and pharmaceutical compositions containing these compounds, especially for transcutaneous administration
JPS63211231A (ja) 1987-02-27 1988-09-02 Sumitomo Pharmaceut Co Ltd 雄性不妊動物の治療剤
US4952581A (en) 1987-04-03 1990-08-28 The Trustees Of Columbia University In The City Of New York Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocular pressure
US5591887A (en) * 1987-04-30 1997-01-07 R-Tech Ueno, Ltd. Prostaglandins of the F series
GB8713747D0 (en) * 1987-06-12 1987-07-15 Unilever Plc Skin treatment composition
US5166178B1 (en) 1987-09-18 1998-07-21 R Tech Ueno Ltd Ocular hypotensive agents
GB2209939B (en) 1987-09-18 1992-01-02 R Tech Ueno Ltd The use of 13,14-dihydro-15-keto-prostaglandins as ocular hypotensive agents
SE8703854D0 (sv) 1987-10-07 1987-10-07 Pharmacia Ab Prostaglandinderivat for behandling av glaukom eller okuler hypertension
AU619543B2 (en) 1988-05-11 1992-01-30 Sucampo Ag Use of 15-ketoprostaglandin e or f compounds for uterine contraction
US5296504A (en) * 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5321128A (en) * 1988-09-06 1994-06-14 Kabi Pharmacia Ab Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US6187813B1 (en) * 1990-04-10 2001-02-13 Pharmacia & Upjohn Aktiebolag Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
ES2317964T5 (es) * 1988-09-06 2015-02-20 Pfizer Health Ab Derivado de prostaglandina-F2alfa para el tratamiento de glaucoma o hipertensión ocular
US4891961A (en) 1988-09-09 1990-01-09 Anton Tsamas Key ring
US5194429A (en) * 1988-10-01 1993-03-16 K.K. Ueno Seiyaku Oyo Kenkyujo Ocular hypotensive agents
US4968812A (en) 1989-06-23 1990-11-06 Shell Oil Company Spirolactonelactams
JPH0737389B2 (ja) 1989-08-29 1995-04-26 久光製薬株式会社 プロスタグランジンｅ１含有の軟膏剤
JPH0737390B2 (ja) 1989-08-29 1995-04-26 久光製薬株式会社 軟膏組成物
CA1339132C (en) 1989-09-12 1997-07-29 Johan W. Stjernschantz Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
CA2030345C (en) * 1989-11-22 1998-12-08 Ryuji Ueno Use of 15-keto-prostaglandin compound for improvement of encephalic function
JPH0627942Y2 (ja) 1989-12-14 1994-07-27 松下電器産業株式会社 ヒューズホルダー付コンデンサー
JPH0720909Y2 (ja) 1989-12-14 1995-05-15 松下電器産業株式会社 コンデンサー
TW224942B (de) * 1990-04-04 1994-06-11 Adka Ueno Kk
US5302617A (en) * 1990-04-27 1994-04-12 Kabushikikaisha Ueno Seiyaku Oyo Kenkyuio Biochemical treatment with 15-dehydroxy-16-oxoprostaglandin compounds
US5063057A (en) 1990-09-26 1991-11-05 Elizabeth Arden Co., Division Of Conopco, Inc. Cosmetic capsules
DE4024347A1 (de) 1990-07-27 1992-01-30 Schering Ag Cyclopentanderivate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
JPH04300833A (ja) 1991-03-29 1992-10-23 Green Cross Corp:The プロスタグランジンｅ１　含有脂肪乳剤充填噴霧剤
US5378840A (en) 1992-04-16 1995-01-03 G. D. Searle & Co. Substituted dibenzoxazepine compounds
US5312832A (en) * 1991-05-17 1994-05-17 Allergan, Inc. Ocular hypotensive 2-decarboxyl-2-acylthioalkyl prostaglandin derivatives
US5288754A (en) * 1992-02-04 1994-02-22 Allergan, Inc. Polar C-1 esters of prostaglandins
US5641494A (en) * 1992-03-20 1997-06-24 Janssen Pharmaceutica N.V. Agent for regulating the greasiness of the skin
US5578643A (en) 1992-05-20 1996-11-26 Loyola University Of Chicago Protective prostaglandins for use in conjunction with chemotherapeutic agents
US5422371A (en) * 1992-05-27 1995-06-06 Arch Development Corp. Methods and compositions for inhibiting 5α-reductase activity
JP3102141B2 (ja) * 1992-05-29 2000-10-23 東レ株式会社 養毛育毛剤
US5817694A (en) * 1992-06-08 1998-10-06 New Pharma International Corp. 16-methyl-11,16-dihydroxy-9-oxoprost-2,13-dien-1-oic acid and derivatives
US5409911A (en) * 1992-09-11 1995-04-25 Merck & Co., Inc. Prostaglandin analog for treating osteoporosis
US5834498A (en) 1992-09-21 1998-11-10 Allergan Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5688819A (en) 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5972991A (en) * 1992-09-21 1999-10-26 Allergan Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5352708A (en) * 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
EP0664707B1 (de) 1992-10-13 1997-06-04 Alcon Laboratories, Inc. Zusammensetzungen zur behandlung von glaukoma die prostaglandine und clonidinderivate enthalten
US5332730A (en) * 1992-10-16 1994-07-26 Allergan, Inc. Azido derivatives of cyclopentane heptanoic or heptenoic acid
US5340813A (en) * 1992-11-09 1994-08-23 Cell Therapeutics, Inc. Substituted aminoalkyl xanthine compounds
DE4238830A1 (de) 1992-11-17 1994-05-19 Anton Felder Verfahren zum hydraulischen Verzweigen einer offenen Strömung sowie hydraulisch arbeitende Kanalverzweigung
US5670506A (en) * 1993-04-05 1997-09-23 Cell Therapeutics, Inc. Halogen, isothiocyanate or azide substituted xanthines
US5395932A (en) * 1993-04-30 1995-03-07 G. D. Searle & Co. 2,3-,4-,5-,6-,7-,8-,9- and/or 10-substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
US5985597A (en) * 1993-05-26 1999-11-16 Merck Frosst Canada, Inc. DNA encoding prostaglandin receptor EP1
ATE172471T1 (de) 1993-06-25 1998-11-15 Merck Frosst Canada Inc Prostaglandin rezeptor ep3 und kodierende dns
US5869281A (en) * 1993-06-25 1999-02-09 Merck Frosst Canada Inc. DNA encoding prostaglandin receptor FP
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
US5605814A (en) * 1993-08-31 1997-02-25 Merck Frosst Canada Inc. DNA encoding human prostaglandin receptor EP2
US5516652A (en) * 1993-10-06 1996-05-14 Merck Frosst Canada Inc. DNA encoding prostaglandin receptor IP
FR2711060B1 (fr) 1993-10-13 1995-11-17 Oreal Procédé pour modifier la pousse des poils et/ou des cheveux et compositions utilisables à cet effet.
SE9303444D0 (sv) 1993-10-20 1993-10-20 Kabi Pharmacia Ab New use of prostaglandins
WO1995011033A1 (en) 1993-10-22 1995-04-27 Commonwealth Scientific And Industrial Research Organisation Polyoxometallates in the treatment of flavivirus infections
SE9303627D0 (sv) * 1993-11-03 1993-11-03 Kabi Pharmacia Ab Method and means for prevention of cataract
US5431881A (en) 1993-12-10 1995-07-11 Palacios; Henry J. Treatment of hair loss and dermatological problems
KR100345943B1 (ko) * 1993-12-20 2002-11-30 후지사와 야꾸힝 고교 가부시키가이샤 4,5-디아릴옥사졸유도체
US6124344A (en) 1993-12-28 2000-09-26 Allergan Sales, Inc. Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5545665A (en) * 1993-12-28 1996-08-13 Allergan Cyclopentane(ene) heptenoic or heptanoic acids and derivatives thereof useful as therapeutic agents
US5458883A (en) 1994-01-12 1995-10-17 Duke University Method of treating disorders of the eye
US5462968A (en) 1994-01-19 1995-10-31 Allergan, Inc. EP2 -receptor agonists as agents for lowering intraocular pressure
SE9403158D0 (sv) * 1994-09-21 1994-09-21 Pharmacia Ab New use of prostaglandins
US5698733A (en) 1994-09-30 1997-12-16 Alcon Laboratories, Inc. Use of 9-deoxy prostaglandin derivatives to treat glaucoma
US5885974A (en) * 1994-12-06 1999-03-23 Michael M. Danielov Therapeutic methods utilizing naturally derived bio-active complexes and delivery systems therefor
US6043264A (en) * 1995-01-06 2000-03-28 Toray Industries, Inc. Benzene-condensed heterocyclic derivatives and their uses
WO1996023066A2 (en) * 1995-01-26 1996-08-01 Merck Frosst Canada Inc. Prostaglandin receptor, dp
FR2730811B1 (fr) 1995-02-17 1997-03-21 Oreal Procede pour diagnostiquer et/ou suivre l'evolution d'un desordre capillaire et/ou mesurer l'efficacite d'un traitement applique pour combattre un desordre capillaire
US5885766A (en) * 1995-02-17 1999-03-23 Societe L'oreal S.A. Method of screening of substances for their effect on the expression of mediators of inflammation in a hair follicle
CA2221110C (en) 1995-05-18 2009-08-04 Allergan Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents for the treatment of ocular hypertension
US6169111B1 (en) * 1995-06-07 2001-01-02 Alcon Laboratories, Inc. Conformationally rigid aryl prostaglandins for use in glaucoma therapy
WO1997001534A1 (en) 1995-06-26 1997-01-16 Teijin Limited Prostaglandins and process for producing the same
TW401408B (en) 1995-07-21 2000-08-11 Fujisawa Pharmaceutical Co Heterocyclic compounds having prostaglandin I2 agonism
HUP9601442A3 (en) * 1995-07-25 1999-03-29 Panacea Biotec Ltd Nes antinflammatory and analgetic pharmaceutical compositions, containing nimesulid for transdermal use, and process for producing them
US5661178A (en) 1995-09-01 1997-08-26 Allergan Method for effecting vasodilation with (1,5-inter)aryl prostaglandin derivatives
US6251436B1 (en) 1995-09-29 2001-06-26 L.A.M. Pharmaceutical Corporation Drug preparations for treating sexual dysfunction
WO1997015319A1 (en) 1995-10-23 1997-05-01 Queen's University At Kingston Method and pharmaceutical composition for chondrostimulation with a prostaglandin (e.g. misoprostol) and tgf-beta, optionally in combination with igf-1
US6441047B2 (en) 1995-11-17 2002-08-27 Alcon Manufacturing Ltd.. Combination therapy for treating glaucoma
AU1138097A (en) 1995-12-22 1997-07-17 Alcon Laboratories, Inc. Combinations of prostaglandins and miotics for lowering intraocular pressure
US5994397A (en) 1995-12-22 1999-11-30 Alcon Laboratories, Inc. Substituted tetrahydrofuran analogs of prostaglandins as ocular hypotensives
US5814660A (en) 1995-12-22 1998-09-29 Alcon Laboratories, Inc. 9-oxa prostaglandin analogs as ocular hypotensives
WO1997023225A1 (en) 1995-12-22 1997-07-03 Alcon Laboratories, Inc. Combinations of dp and fp type prostaglandins for lowering iop
US5866602A (en) 1995-12-22 1999-02-02 Alcon Laboratories, Inc. Keto-substituted tetrahydrofuran analogs of prostaglandins as ocular hypotensives
AUPN814496A0 (en) 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US5703108A (en) 1996-02-28 1997-12-30 Pfizer Inc. Bone deposition by certain prostaglandin agonists
US5741810A (en) 1996-02-29 1998-04-21 Allergan Cyclopentane heptan(ene)oic acid, 2- heteroarylalkenyl derivatives as therapeutic agents
US5658897A (en) * 1996-04-08 1997-08-19 Allergan Cyclopentane(ene) heptanoic or cyclopentane(ene) heptenoic acid, 2-hydrocarbyl phosphinyloxyalkyl or phosphonamidoalkyl as therapeutic agents
US5990168A (en) 1996-04-18 1999-11-23 Alberta Cancer Board Methods and compositions for the treatment of ataxia telangiectasia
JP3049593B2 (ja) * 1996-05-01 2000-06-05 株式会社ビメーク 育毛・養毛剤
ES2182088T3 (es) 1996-06-10 2003-03-01 Sucampo Ag Antagonista de la endotelina.
AU3588797A (en) 1996-07-03 1998-01-21 Board Of Regents Of The University Of Oklahoma, The Enhancement of skin pigmentation by prostaglandins
US5792851A (en) * 1996-09-03 1998-08-11 Albert Einstin College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Human prostaglandin transporter
ATE221048T1 (de) 1996-09-17 2002-08-15 Asahi Glass Co Ltd Fluorierte prostaglandinderivate und medikamente
JP4004109B2 (ja) 1996-09-17 2007-11-07 参天製薬株式会社 含フッ素プロスタグランジン誘導体および医薬
US5827508A (en) 1996-09-27 1998-10-27 The Procter & Gamble Company Stable photoprotective compositions
WO1998019680A1 (en) 1996-11-01 1998-05-14 Alcon Laboratories, Inc. Use of a combination of carbonic anhydrase inhibitors and prostaglandins for treating glaucoma
AU5436198A (en) 1996-11-12 1998-06-03 Alcon Laboratories, Inc. 11-halo prostaglandins for the treatment of glaucoma or ocular hypertension
AU5258698A (en) 1996-11-12 1998-06-03 Alcon Laboratories, Inc. 15-ketal prostaglandins for the treatment of glaucoma or ocular hypertension
DE69705421T2 (de) 1996-11-12 2002-05-16 Alcon Laboratories, Inc. 15-fluoro-prostaglandine als augendrucksenkende mittel
CN1237157A (zh) 1996-11-12 1999-12-01 阿尔康实验室公司 作为眼压降低剂的前列腺素的顺式－△4类似物
TW523506B (en) 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
UA59384C2 (uk) 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
ATE390917T1 (de) 1996-12-20 2008-04-15 Pfizer Prävention und behandlung von skeletterkrankungen mit ep2 subtyp selektiven prostaglandin e2 agonisten
JPH10265454A (ja) * 1997-01-27 1998-10-06 Ono Pharmaceut Co Ltd ３，７−ジチアプロスタン酸誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤
NO317155B1 (no) * 1997-02-04 2004-08-30 Ono Pharmaceutical Co <omega>-cykloalkyl-prostagladin-E<N>2</N>-derivater
DE69823852T2 (de) * 1997-02-04 2005-05-19 Johnstone, Murray A., Seattle Verfahren zur förderung des haarwuchses und entwicklung des haarsystems
KR20000070903A (ko) 1997-02-10 2000-11-25 오노 야꾸힝 고교 가부시키가이샤 11,15-ｏ-디알킬프로스타글란딘 ｅ 유도체, 이것의 제조 방법 및 이것을 유효 성분으로 함유하는 약제
CA2253717A1 (en) 1997-02-27 1998-09-03 Toray Industries Inc. Drugs for ameliorating pulmonary circulation
JP2001514628A (ja) 1997-03-07 2001-09-11 アルコン ラボラトリーズ，インコーポレイテッド 緑内障治療に用いるための１３−チアプロスタグランジン
US6030959A (en) * 1997-04-04 2000-02-29 Monsanto Company Gastro-specific prodrugs
JP3217293B2 (ja) * 1997-04-17 2001-10-09 株式会社アールテック・ウエノ 発毛・育毛剤
IT1291633B1 (it) 1997-04-22 1999-01-11 Pharmaconsult S A S Uso dell'alfa-metil-p-tirosina per inibire la produzione di melanina nei melanociti dell'iride
EP1007028A4 (de) * 1997-05-09 2002-06-05 Behandlung von glaukom mit 8-iso-prostaglandinen
WO1998053809A1 (en) 1997-05-30 1998-12-03 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
WO1998058911A2 (en) 1997-06-23 1998-12-30 Pfizer Inc. Prostaglandin agonists
SE9702706D0 (sv) 1997-07-11 1997-07-11 Pharmacia & Upjohn Ab Prostaglandin derivatives devoid of side-effects for the treatment of glaucoma
WO1999012553A1 (en) 1997-09-08 1999-03-18 Idec Pharmaceuticals Corporation Methods for producing human antibodies in scid mice using dendritic cells
WO1999012556A1 (en) 1997-09-08 1999-03-18 The Public Health Research Institute Of The City Of New York, Inc. HIV-1 gp120 V1/V2 DOMAIN EPITOPES CAPABLE OF GENERATING NEUTRALIZING ANTIBODIES
CA2303460C (en) 1997-09-09 2011-06-21 Mariel Therapeutics, Inc. Synergistic effects of op/bmp morphogens and gdnf/ngf neurotrophic factors
WO1999012899A1 (en) 1997-09-09 1999-03-18 The Procter & Gamble Company A process for making prostaglandin f analogs
CA2304108A1 (en) 1997-09-09 1999-03-18 The Regents Of The University Of California Inhibition of apoptotis using prosaposin receptor agonists
US6156799A (en) 1997-09-09 2000-12-05 The Procter & Gamble Company Method of increasing bone volume using non-naturally-occurring FP selective agonists
IL134839A0 (en) * 1997-09-09 2001-05-20 Procter & Gamble Aromatic c16-c20-substituted tetrahydro prostaglandins useful as fp agonists
AU752925B2 (en) 1997-09-09 2002-10-03 F. Hoffmann-La Roche Ag Fracture healing using PTHrP analogs
DK1012137T3 (da) 1997-09-09 2003-03-10 Procter & Gamble Aromatiske C-16-C-20-substituerede tetrahydro-prostaglandiner og deres anvendelse som prostaglandin FP-agonister
ES2253826T3 (es) * 1997-09-09 2006-06-01 Duke University Prostaglandinas aromaticas tetrahidro sustituidas por c16-c20 utilizadas como agonistas fp.
WO1999012897A1 (en) 1997-09-09 1999-03-18 The Procter & Gamble Company A process for making epoxide intermediates
PL339297A1 (en) 1997-09-09 2000-12-04 Procter & Gamble Method of inctrasing bone volume
AUPO907697A0 (en) 1997-09-09 1997-10-02 Day, Robert Edward Chemical supplementation of bone
AU731842B2 (en) 1997-09-10 2001-04-05 Merck & Co., Inc. 9a-azalides as veterinary antimicrobial agents
AU9312598A (en) 1997-09-10 1999-03-29 Allegheny University Of The Health Sciences Inhibitors of collagen assembly
WO1999012563A2 (en) 1997-09-11 1999-03-18 The Governemnt Of The United States Of America, Represented By The Department Of Health And Human Services Mucosal cytotoxic t lymphocyte responses
DK1011699T3 (da) 1997-09-11 2002-03-11 Purdue Research Foundation Galactosidase-modificeret submucosavæv
JP2001515707A (ja) 1997-09-12 2001-09-25 スミスクライン・ビーチャム・コーポレイション 新規原核生物ポリヌクレオチド、ポリペプチドおよびそれらの使用
WO1999013881A1 (en) 1997-09-17 1999-03-25 Toray Industries, Inc. Cervical maturing agent
WO1999015502A1 (en) 1997-09-19 1999-04-01 Shionogi & Co., Ltd. Compounds having [2.2.1]bicyclo skeleton
UA67754C2 (uk) 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
US6124314A (en) 1997-10-10 2000-09-26 Pfizer Inc. Osteoporosis compounds
CA2306837C (en) 1997-10-28 2007-05-08 Vivus, Inc. Treatment of female sexual dysfunction
AUPP010397A0 (en) 1997-10-30 1997-11-20 Vaisman, Jakov Method and composition for treatment of sexual dysfunction
AU1373499A (en) 1997-11-14 1999-06-07 United Therapeutics Corporation Use of 9-deoxy-2', 9-alpha-methano-3- oxa-4,5,6- trinor-3, 7-(1',3'-interphenylene) -13,14-dihydro- prostaglandin f1 to treat peripheral vascular disease
US5877211A (en) * 1997-11-21 1999-03-02 Allergan EP2 receptor agonists as neuroprotective agents for the eye
US6099870A (en) 1997-12-18 2000-08-08 Johnson & Johnson Consumer Companies, Inc. Methods for improving the health of hair and scalp
CA2314369A1 (en) 1997-12-18 1999-06-24 Nathan Earl Scott Prostaglandin e2/f2.alpha. combination for treating impotence and enhancing sexual arousal
WO1999032641A1 (en) 1997-12-22 1999-07-01 Unilever N.V. A process for site-directed integration of multiple copies of a gene in a mould
US6232344B1 (en) * 1997-12-22 2001-05-15 Alcon Laboratories, Inc. 13-Oxa prostaglandins for the treatment of glaucoma and ocular hypertension
US5955575A (en) 1997-12-22 1999-09-21 Hopital Sainte-Justine Antagonists of G-protein-coupled receptor
WO1999033794A1 (en) 1997-12-25 1999-07-08 Ono Pharmaceutical Co., Ltd. φ-CYCLOALKYL-PROSTAGLANDIN E2 DERIVATIVES
GB2330307A (en) 1998-02-07 1999-04-21 Glaxo Group Ltd EP4 Receptor antagonists as bone resorption inhibitors
WO1999047497A2 (en) 1998-03-13 1999-09-23 Merck Frosst Canada & Co. Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
US6444840B1 (en) 1998-03-31 2002-09-03 The Procter & Gamble Co. C11 oxymyl and hydroxylamino prostaglandins useful as FP agonists
ES2244208T3 (es) 1998-03-31 2005-12-01 Duke University Prostaglandinas oximil e hidroxilamino c11 utilizados como antagonistas fp.
KR20010042286A (ko) 1998-03-31 2001-05-25 데이비드 엠 모이어 의약으로 유용한 ｃ１１ 옥시밀 및 히드록실아미노프로스타글란딘
ES2211083T3 (es) 1998-05-25 2004-07-01 Taisho Pharmaceutical Co., Ltd Derivado de prostaglandina.
US6458549B2 (en) 1998-06-11 2002-10-01 Winthrop-University Hospital Methods of diagnosing renal salt wasting syndrome and Alzheimer's disease and methods of treating the same
US5942545A (en) 1998-06-15 1999-08-24 Macrochem Corporation Composition and method for treating penile erectile dysfunction
US6187818B1 (en) 1998-06-17 2001-02-13 Pharmacia & Upjohn Company Prostaglandins formulation and process
WO2000002450A1 (en) 1998-07-08 2000-01-20 Fibrogen, Inc. Method for treatment of fibrosis related diseases by the administration of prostacyclin derivatives
CA2295512C (en) 1998-07-14 2009-05-26 Alcon Laboratories, Inc. Prostaglandin product
TWI249520B (en) 1998-07-15 2006-02-21 Ono Pharmaceutical Co 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient
WO2000004898A1 (en) 1998-07-21 2000-02-03 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
CA2337349A1 (en) 1998-07-21 2000-02-03 Gerald S. Ponticello Ophthalmic compositions for treating ocular hypertension
US6284234B1 (en) * 1998-08-04 2001-09-04 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents
WO2000009557A1 (fr) 1998-08-12 2000-02-24 Kazusa Dna Research Institute Foundation Nouveau gene et nouvelle proteine pgth codee par ce gene
EP1114816A4 (de) 1998-09-14 2002-09-04 Ono Pharmaceutical Co $g(v)-SUBSTITUIERTE PHENYL-PROSTAGLANDIN-E-DERIVATE UND SIE ALS AKTIVEN BESTANDTEIL ENTHALTENDE MEDIKAMENTE
AUPP608898A0 (en) 1998-09-23 1998-10-15 Fujisawa Pharmaceutical Co., Ltd. New use of prostaglandin E2 antagonists
US6121253A (en) * 1998-11-20 2000-09-19 Merck Frosst Canada & Co. Prostaglandin conjugates for treating or preventing bone disease
IL144765A0 (en) 1999-03-01 2002-06-30 Pfizer Prod Inc Oxamic acids and derivatives as thyroid receptor ligands
AU763715B2 (en) * 1999-03-05 2003-07-31 Duke University C16 unsaturated fp-selective prostaglandins analogs
WO2000051980A1 (en) 1999-03-05 2000-09-08 The Procter & Gamble Company C16 unsaturated fp-selective prostaglandins analogs
EP1169061A1 (de) 1999-03-12 2002-01-09 Alcon Laboratories, Inc. Kombinationstherapie zur behandlung von glaukom
EP1202999B1 (de) 1999-08-04 2003-06-18 The Procter & Gamble Company Neue 2-decarboxy-2-phosphinico prostaglandin f analoge
US6894175B1 (en) * 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
US6548535B2 (en) * 2000-01-18 2003-04-15 Merck & Co., Inc. Method for treating ocular hypertension
IL143477A (en) 2001-05-31 2009-07-20 Finetech Pharmaceutical Ltd Process for the preparation of 17-phenyl-18,19,20-trinor-pgf2?? and its derivatives
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020037914A1 (en) * 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
WO2001072268A1 (en) * 2000-03-31 2001-10-04 Toray Industries, Inc. Hair growth or hair formation controlling agents
US20020146439A1 (en) * 2000-03-31 2002-10-10 Delong Mitchell Anthony Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
FR2812190B1 (fr) * 2000-07-28 2003-01-31 Oreal Utilisation d'agonistes non prostanoiques des recepteurs des prostaglandines ep-2 et/ou ep-4 comme agent cosmetique permettant d'attenuer, de diminuer ou d'arreter la chute des cheveux et des poils
FR2812193B1 (fr) 2000-07-28 2003-10-24 Oreal Utilisation d'antagoniste des recepteurs des prostaglandines ep-2 et/ou ep-4 pour attenuer, diminuer ou stopper la pousse des cheveux et des poils dans des preparations cosmetiques
FR2812191B1 (fr) 2000-07-28 2003-10-17 Oreal Utilisation d'agonistes du recepteur des prostaglandines e2 (ep-3) pour attenuer, diminuer ou stopper la pousse des cheveux et des poils dans des preparations cosmetiques
AU2001259099B2 (en) 2001-02-22 2005-12-22 Skyepharma Canada Inc. Fibrate-statin combinations with reduced fed-fasted effects
EP1298223A3 (de) 2001-09-28 2003-07-23 Pfizer Products Inc. Methoden die mit der A-C Wiederholungs-Z-Sequenz stromaufwärts des Aldosereduktasegens in Zusammenhang stehen
SE0104334D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
US20040082013A1 (en) 2002-01-24 2004-04-29 Regan John W Methods for screening for substances which inhibit fp prostanoid receptor interaction with a compound having pgf2alpha activity and methods of treating cancer
US7351404B2 (en) 2002-02-04 2008-04-01 Allergan, Inc. Method of enhancing hair growth
US8758733B2 (en) 2002-02-04 2014-06-24 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
AU2003207900A1 (en) 2002-03-18 2003-09-29 Pfizer Products Inc. Methods of treatment with selective ep4 receptor agonists
US7186707B2 (en) * 2002-04-01 2007-03-06 University Of Florida Prodrugs for use as ophthalmic agents
GB0208785D0 (en) 2002-04-17 2002-05-29 Medical Res Council Treatment methtods
US7320967B2 (en) 2002-04-23 2008-01-22 L'oreal Cosmetic composition, method of cosmetic treatment and preparation of a composition for promoting the growth and/or preventing or delaying the loss of hair
US6573294B1 (en) * 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure
US7521530B2 (en) 2002-06-11 2009-04-21 Universite De Montreal Peptides and peptidomimetics useful for inhibiting the activity of prostaglandin F2α receptor
US20030199590A1 (en) 2002-07-25 2003-10-23 Cagle Gerald D Prostaglandin analogues for promotion of hair growth
JP4300833B2 (ja) 2003-03-17 2009-07-22 ソニー株式会社 半導体発光素子の製造方法
US7589233B2 (en) 2003-07-29 2009-09-15 Signature R&D Holdings, Llc L-Threonine derivatives of high therapeutic index
US7045634B2 (en) 2003-09-05 2006-05-16 Allergan, Inc. Prostamide receptor antagonists
US20050058614A1 (en) * 2003-09-15 2005-03-17 Allergan, Inc. Methods for the treatment of gray hair using cyclopentane(ene) heptan(en)oic acid amides
US7070768B2 (en) 2003-09-25 2006-07-04 Allergan, Inc. Method for imparting artificial tan to human skin
US20050112075A1 (en) 2003-11-25 2005-05-26 Hwang Cheng S. Reduction of hair growth
EP1722780A4 (de) 2003-11-26 2008-12-17 Univ Duke Verfahren zur prävention oder behandlung von glaukom
US7288029B1 (en) 2005-01-19 2007-10-30 Gkn Driveline North America, Inc. Propshaft with crash-worthiness
WO2006047466A2 (en) 2004-10-21 2006-05-04 Duke University Ophthamological drugs
GB0506759D0 (en) 2005-04-02 2005-05-11 Medical Res Council Combination treatment methods
WO2007123818A2 (en) 2006-04-18 2007-11-01 Nitromed, Inc. Organic nitric oxide enhancing salts of prostaglandins, compositions and methods of use
KR101281965B1 (ko) 2006-04-24 2013-07-03 제이에스알 가부시끼가이샤 중합체 및 이를 함유하는 감광성 수지 조성물
US20070254920A1 (en) 2006-04-26 2007-11-01 Aerie Pharmaceuticals, Inc. Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use
US7868032B2 (en) 2006-10-18 2011-01-11 Allergan, Inc. Prostamide receptor antagonists
JP5095269B2 (ja) 2007-06-05 2012-12-12 北海道エア・ウォーター株式会社 通信システム
US20090018204A1 (en) * 2007-07-13 2009-01-15 Brinkenhoff Michael C Composition and method for enhancing hair growth
EP2349242B1 (de) 2008-10-29 2018-12-05 Novaer Holdings, Inc. Aminosäuresalze von prostaglandinen
US8722739B2 (en) * 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8623918B2 (en) * 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
WO2010108012A1 (en) 2009-03-18 2010-09-23 Duke University Compositions and methods for promoting nasal patency and treating neurogenic bladder using prostaglandins
EP3871671A3 (de) 2009-07-29 2022-03-09 Olsen, Elise Fp rezeptorantagonisten zur hemmung von haarwachstum
WO2011119748A1 (en) 2010-03-24 2011-09-29 Allergan, Inc. Compositions comprising a prosamide for treating hair loss, hair thinning, hair color loss

Also Published As

Publication number Publication date
US8906962B2 (en) 2014-12-09
US20150238469A1 (en) 2015-08-27
CN101897700A (zh) 2010-12-01
JP2020023579A (ja) 2020-02-13
CN101229171A (zh) 2008-07-30
US20170348214A1 (en) 2017-12-07
CN1522135A (zh) 2004-08-18
WO2001074315A2 (en) 2001-10-11
WO2001074315A3 (en) 2002-02-21
US8541466B2 (en) 2013-09-24
US20160106651A1 (en) 2016-04-21
CN100384425C (zh) 2008-04-30
US20020172693A1 (en) 2002-11-21
US9579270B2 (en) 2017-02-28
US20050222232A1 (en) 2005-10-06
JP2017101083A (ja) 2017-06-08
US7388029B2 (en) 2008-06-17
US20190175475A1 (en) 2019-06-13
JP2012046546A (ja) 2012-03-08
JP2003528899A (ja) 2003-09-30
US20090286769A1 (en) 2009-11-19
CA2401731E (en) 2001-10-11
ES2252215T3 (es) 2006-05-16
DE60115000D1 (de) 2005-12-22
JP2019001828A (ja) 2019-01-10
CA2401731C (en) 2007-05-29
EP1267807B1 (de) 2005-11-16
DE60115000T2 (de) 2006-08-17
US20140024587A1 (en) 2014-01-23
JP2015134831A (ja) 2015-07-27
JP2014043451A (ja) 2014-03-13
US20200330479A1 (en) 2020-10-22
CA2401731A1 (en) 2001-10-11
EP1267807A2 (de) 2003-01-02
US20080103184A1 (en) 2008-05-01
AU2001253039A1 (en) 2001-10-15

Similar Documents

Publication Publication Date Title
ATE309775T1 (de) Die verwendung von prostaglandin f analoga zur herstellung von zusammensetzungen für die behandlung von haarausfall.
ATE312587T1 (de) Zusammenseztungen und verfahren zur behandlung von haarausfall unter verwendung von c16-c20 aromatischen tetrahydro-prostaglandinen
AU2001253038A1 (en) Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
WO2001074307A3 (en) Compositions and methods for treating hair loss using oximyl- and hydroxylamino- prostaglandins
TW200512007A (en) Cosmetic compositions containing fullerene clusters
DE69429450D1 (de) Die verwendung von angiotensin iii und seiner analoge für die gewebeheilung
ATE245416T1 (de) Neue fettanaloge zur behandlung von diabetes
DE3851203D1 (de) Gebrauch von GHL-Cu Derivaten für die Herstellung eines Medikaments zur Stimulierung des Haarwachstums.
ATE103487T1 (de) Betaeubungs- und feuchtigkeitszusammensetzung und verfahren zur herstellung.
SI2298338T1 (sl) Laktoferinski sestavki in postopki za zdravljenjekožnih ran
DE50107180D1 (de) Haartonikum zur Vorbeugung oder Behandlung von Haarausfall
AU2003274052A8 (en) Use of cellulose microbeads to make the skin matt
ES2127490T3 (es) Utilizacion de un aceite rico en acido petroselenico como agente hidratante.
EE9700225A (et) Meetod diabetes mellituse raviks, kasutades KKF
ATE55695T1 (de) Verwendung von defibrotid zur herstellung pharmazeutischer zusammensetzungen zur behandlung peripherer arteriopathien.
DE69829202D1 (de) Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen
ATE421313T1 (de) Verwendung einer dihydrochalcon-reichen phenolischen fraktion für eine kosmetische behandlung
ATE123409T1 (de) Verwendung von vitamin d verbindungen zur herstellung einer kosmetischen zusammensetzung und anwendung dieser zur verbesserung der hautbeschaffenheit.
DE60336187D1 (de) Verwendung von einem Extrakt von einem nicht-photosynthetischen faserigen Bakterium zur Beförderung der Herstellung von Superoxid-dismutase
MX160743A (es) Composicion para tratar el cabello
EP0274104A3 (de) 13-cis-Retinsäure zur Verwendung in Präparaten gegen alternde Haut
ATE259214T1 (de) Parfümzusammensetzung
DE69820911D1 (de) Verwendung einer Verbindung zur Herstellung eines Medikaments zur Behandlung von Alopecia oder zur Förderung des Haarwuchses bei Tieren
ATE291896T1 (de) Ribose-haltige kosmetische zusammensetzung
AU8988901A (en) Sulphur analogues of 21-hydroxy-6,19-oxidoprogesterone (21oh-6op) for treating excess of glucocorticoids

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties